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Abstract
The neurochemical effects of partial D2-like agonist
(i.e., terguride) to alter striatal DOPA accumulation
under high and low dopaminergic tone was examined in
preweanling rats. To this end, they were injected with
reserpine or GBL to create a state of low dopaminergic
tone and saline was used to create a state of high
dopaminergic tone.
In Experiment 1, preweanling rats were treated either
repeatedly or acutely with reserpine or saline. The rats
in the repeated condition received daily reserpine
injections from PD 16 - PD 20, and rats in the acute
condition only received reserpine treatment on PD 20. On
PD 21, all rats were injected with the full D2-like
antagonist haloperidol, the partial D2-like agonist
terguride, the full D2-like agonist quinpirole, or saline.
They were then injected with NSD 1015 and striatal DOPA
accumulation was measured. As expected, the results
showed that both terguride and quinpirole reduced striatal
DOPA accumulation during a state of low dopaminergic tone.
During a state of high dopaminergic tone, terguride had
iii
similar effects as haloperidol, increasing in DOPA
accumulation.
In Experiments 2 and 3, terguride's ability to
modulate dopamine synthesis under states of low or high
dopaminergic tone was assessed using impulse flow
inhibitor y-butyrolactone (GBL) or saline, respectively.
Preweanling rats were injected with haloperidol,
quinpirole, terguride, or saline on PD 21. After the drug
injections, they were injected with GBL followed by NSD 
1015. The results showed that(terguride, like quinpirole, 
partially inhibited the GBL-induced increase in striatal
DOPA accumulation. On the other hand, terguride had a
haloperidol-like effect under a state of high dopaminergic
tone. When considered together, the results from all
three experiments indicate that terguride have agonist­
like (quinpirole-like) effects under a low dopaminergic
tone and antagonist-like (haloperidol-like) effects under
a high dopaminergic tone during preweanling period.
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CHAPTER ONE
OVERVIEW
General Overview
In the United States, many people are under going
rehabilitation for psychostimulant (e.g., cocaine,
amphetamine, and methamphetamine) addiction (National
Institute on Drug Abuse, 1999). Most people seek
psychostimulant drugs for their reinforcing effects. When
these types of drugs are taken qver a long period of time,
drug abusers will go through a withdrawal phase when the
drugs are not present. Common symptoms of psychostimulant
withdrawal are psychomotor retardation, depression,
fatigue, and decreased motivation for natural reward (e.g.,
food seeking behavior)(Orsini, Koob, &'Pulvirenti, 2001).
In animal models, withdrawal symptoms are usually measured
by observing psychomotor retardation after long exposure
to psychostimulant drugs (Pulvirenti & Koob, 1994) .
According to Pulvirenti and Koob (1994), drug
withdrawal is due to a reduction in dopamine
neurotransmission, which is caused by increased
sensitivity of D2-like autoreceptors. Recently, partial
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D2-like agonists (e.g., aripiprazole, preclamol, terguride,
SDZ 208-911, and SDZ 208-912) have received much attention
as potential pharmacotherapies because of their unique
property of "normalizing" dopamine neurotransmission
(Pulvirenti, Balducci, Piercy, & Koob, 1998) .
Specifically, partial D2-like agonists act as either
agonists or antagonists depending on intrinsic
dopaminergic activity (for a review, see Clark, Hjorth, &
Carlsson, 1985). Thus, partial D2-like agonists act as
antagonists when the dopamine system is stimulated, but
act as agonists when the dopamine system is depressed.
For these reasons, partial D2-like agonists should block
the rewarding effects of psychostimulants while at the
same time maintaining normal dopamine tone. The latter
effect could potentially alleviate drug withdrawal and
craving.
The antagonistic effects of partial D2-like agonists
have been amply shown in animal studies. For example,
cocaine or amphetamine self-administration is
significantly reduced when partial D2-like agonists are
given to rodents and monkeys (Callahan & Cunningham, 1993;
Pulvirenti, Smith, & Koob, 1994). It has also been
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demonstrated that partial D2-like agonists reduce
amphetamine-induced stereotyped behavior and locomotor
activity (Clark, Furmidge, Petry, Tong, Ericsson, &
Johnson, 1991). Thus, partial D2-like agonists behave as
dopamine antagonists when co-administered with indirect
dopamine agonists such as amphetamine and cocaine
(Pulvirenti & Koob, 1994).
Interestingly, partial D2-like agonists have
agonistic effects when dopamine neurotransmission is
depressed. For example, Orsini et al. (2001) demonstrated
that terguride was able to increase saccharin-reinforced
responding in dopamine-depleted ,rats. Normally, rats
going through amphetamine withdrawal (i.e., a state of low
!■
dopaminergic tone) exhibit suppressed responding for a
natural reward (e.g., saccharin)1. However, tergurideI
increases responding for saccharin in a state of low
dopaminergic tone, suggesting that this partial D2-like
agonist was exhibiting agonistic properties. Therefore,
while the majority of behavioral studies have shown that
partial D2-like agonists exhibit antagonistic properties
(Callahan & Cunningham, 1993; Clark et al., 1991;
Pulvirenti & Koob, 1994; Pulvirenti et al., 1994),
3
accumulating evidence suggests that partial D2-like
agonists exhibit agonistic effects on behavior in a state
of low dopaminergic tone (Orsini et al., 2001).
In summary, partial D2-like agonists may serve as
novel pharmacotherapies for psychostimulant addiction. To
date, most studies examining partial D2-like agonists have
used adult animals, while relatively few studies have
examined the effects of partial D2-like agonists during
early ontogeny. This thesis is designed to further
investigate the properties of partial' D2-like agonists in
the developing brain.
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CHAPTER TWO
DOPAMINE RECEPTORS
Dichotomy Based on Receptor Subtypes
There are five different types of dopamine receptors:
Di, D2, D3, D4 and D5. Due to functional and
pharmacological differences, these receptor subtypes are
divided into two families: Dl-like and D2-like receptors.
Dl-like receptors consist of D± and D5 receptors, while DR-
like receptors include D2, D3, and D4 receptors (Seeman &
Van Tol, 1994; Sokoloff, Giros, Martres, Bouthenet, &
Schwartz, 1990; Sunahara, Seeman, Van Tol, & Niznik, 1993)
Dl-like receptors stimulate adenylyl cyclase activity
(Dearry, Gingrich, Falardeau, Fremeau, Bates, & Caron,
1990; Monsma, Mahan, McVittie, Gerfen, & Sibley, 1990),
while D2-like receptors inhibit adenylyl cyclase activity
(Chio, Drong, Riley, Gill, Slightom, & Huff, 1994;
Robinson & Caron, 1996). The mechanisms responsible for
these effects are known, because stimulation of Dl-like
receptors activates a Gs-protein and increases adenylyl
cyclase activity; whereas, stimulation of D2-like
receptors activates a Gi-protein and inhibits adenylyl
5
cyclase activity (Cooper, Bloom, & Roth, 2003) .
Alterations of adenylyl cyclase activity modulate cyclic
adenosine monophosphate (cAMP) formation and protein
kinase A activity (Cooper et al., 2003) . Another
difference between Dl-like and D2-like receptors is the
presence of introns. Dl-like receptors do not have
introns in their coding sequence, whereas D2-like
receptors are interrupted by introns (Civelli, Bunzow, & 
Grandy, 1993; Gingrich & Caron, 1993; O'Dowd, 1993) .
Dl-Like Receptors
As mentioned above, Dl-like receptors consist of the
Di and D5 subtypes. The Dx receptor subtype is the most
widespread dopamine receptor (Dearry et al., 1990),
because it is found throughout various brain regions,
including the striatum, nucleus accumbens, olfactory
tubercles, hypothalamus, thalamus, hippocampus, and 
amygdala (Fremeau, Duncan, Fornaretto, Dearry, Gingrich, 
Breese, & Caron, 1991; Weiner, Levey, Sunahara, Niznik,
O'Dowd & Brann, 1991) . The Dx receptor has been implicated
in unlearned behaviors (Arnt, 1987; Clark & White, 1987),
psychostimulant reward (Di Chiara, 1995), cognition
(Williams & Goldman-Rakic, 1995)-, and incentive responding
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under food deprivation (Di Chiara, Tanda, Cadoni, Acquas,
Bassareo, & Carboni, 1998; Miller, Wickens, & Beninger,
1990) .
The D5 receptor subtype has a function that is very
similar to the Dx receptor. For example, the D5 receptor
plays an important role in reward processes and incentive
motivation (for a review, see'Emilien, Maloteaux, Geurts,
Hoogenberg, & Cragg, 1999). D5 receptors are predominately 
located in forebrain regions. More specifically, D:5
receptors are found in cerebral cortex, lateral and medial
thalamus, striatum, substantia nigra, medial thalamus and
hippocampus (Chio, Lajiness, & Huff, 1994; Huntley,'
Morrison, Prikhozhan, & Sealfon, 1992; Rappaport, Sealfon, 
Prikhozhan, Huntley, & Morrison,' 1993) .
D2-Like Receptors
D2-like receptors mediate- motor movement (Arnt, 1987),
reward mechanisms (Emilien et al., 1999) and they have
also been implicated in schizophrenia- (Arinami, Gao,
Hamaguchi, & Toru, 1997) and substance abuse (Blum, Noble,
Sheridan, Montgomery, Ritchie, Jagadeeswaran, Nogami,
Briggs, & Cohn, 1990.) . For example, D2-receptor deficient
mice show reduced locomotion, rearing, coordinated
7
The D3 and D4 receptor subtypes are involved in motor
movement and neuropsychiatric disorders in both humans and
animals (Accili, Fishburn, Drago, Steiner, Lachowicz, Park
Gauda, Lee, Cool, Sibley, Gerfen, Westphal, & Fuchs, 1996;
Ekman, Nissbrandt, Heilig, Dijkstra, & Eriksson, 1998;
Suzuki, Mihara, Kondo, Tanaka, Nagashima, Otani, & Kaneko,
2000; Wong, Buckle, & Van Tol, 2000) . Interestingly, the D3
receptor subtype has been implicated in the hyperactivity
associated with attention-deficit hyperactivity disorder
(ADHD) (Barr, Wigg, Wu, Zai, Bloom, Tannock, Roberts,
Malone, Schachar, & Kennedy, 2000). In addition, many
researchers believe that there is a strong relationship
between the D4 receptor and novelty seeking behavior
(Benjamin, Li, Patterson, Greenberg, Murphy, & Hamer, 1996
Benjamin, Osher, Kotler, Nemanov, Belmaker, & Ebstein,
2000; Ebstein, Novick, Umansky, Priel, Osher, Blaine,
Bennett, Nemanov, Katz, & Belmaker, 1996; Ebstein, Nemanov
Klotz, Gritsenko, & Belmaker, 1997; Okuyama, Ishiguro,
Nankai, Shibuya, Watanabe, & Arinami, 2000; Strobel, Wehr,
Michel, & Brooke, 1999; Tomitaka, Tomitaka, Otuka, Kim,
Matuki, Sakamoto, & Tanaka, 1999). For example, D4 knock­
out mice show significantly less novelty seeking behavior
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than controls (Dulawa, Grandy, Low, Paulus, & Geyer, 1999).
The D3 receptor subtype is found mostly in the nucleus
accumbens and island of Calleja (MeadOr-Woodruff, Damask,
& Watson, 1994), while the D4 receptor subtype is found in
the cortex, hippocampus, ventral striatum, globus pallidus,
substantia nigra, thalamus, and ventral hypothalamus (for
a review, see Callier, Snapyan, Le Crom, Prou, Vincent, &
Vernier, 2 003) .
Dichotomy Based on Neuroanatomical Location
Postsynaptic Receptors
Postsynaptic receptors are typically stimulated by
neurotransmitter released from nerve terminals. After
dopamine binds to postsynaptic receptors, second messenger
systems are either stimulated or inhibited. Second
messenger activity is modulated via protein
phosphorylation, which regulates many factors including:
cAMP, adenylyl cyclase, voltage- and calcium-dependent
channels, protein kinases, and neurotransmitter release
(Cooper et al., 2003). Typically, the end result of these
actions is that an excitatory or inhibitory postsynaptic
potential is initiated in the dendrites.
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Presynaptic Receptors: Autoreceptors
D2-like autoreceptors are located presynaptically and
are sensitive to the same neurotransmitter that is
released from the terminal (Cooper et al. , 2003) . In
other words, dopamine neurons have specialized receptors,
called autoreceptors that are sensitive to the
neurotransmitter released by the neuron itself.
Conceptually, dopamine autoreceptors play an important
role in self-regulation. Activating these autoreceptors
inhibits dopamine transmission by decreasing dopamine
release, firing rate, and tyrosine hydroxylase activity
(Cooper et al., 2003). In general, dopamine receptor
agonists decrease dopamine synthesis by stimulating
autoreceptors, whereas dopamine receptor antagonists
increase dopamine synthesis by blocking autoreceptors.
The distinction between autoreceptors and
postsynaptic receptors involves more than just location
and function. When compared to.postsynaptic D2-like
receptors, D2-like autoreceptors have a higher affinity for
dopamine and certain dopamine receptor.agonists (Cooper et
al., 2003) . Thus, D2-like autoreceptors are selectively
activated after administration of a partial D2-like
11
agonist (Meller, Bohmaker, Namba, Friedhoff, & Goldstein,
1987).
I
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CHAPTER THREE
DOPAMINE METABOLISM
Dopamine Synthesis
Dopamine is a catecholamine neurotransmitter found
predominately in the central nervous system. Dopamine is
synthesized from the amino acid precursor tyrosine, which
is converted in the cytoplasm to L-3,4-
dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase.
In the cytoplasm, DOPA decarboxylase transforms L-DOPA to
dopamine (see Figure 1) (Cooper et al., 2003) . Tyrosine
hydroxylase is the rate-limiting step in this biosynthetic
pathway.
The main regulatory factors modulating dopamine
synthesis are the firing rate of the neurons, end-product
inhibition, and autoreceptors located in the nerve-endings
(Cooper et al., 2003). In general, stimulation of
somatodendritic autoreceptors inhibits the firing rate of
the neurons via a negative feedback mechanism (for a
review, see Roth & Elsworth, 1995). On the other hand,
antagonizing these autoreceptors increases the firing rate
and, thus, disinhibits the release and synthesis of
13
Tyrosine
Tyrosine
Hydroxylase
L-DOPA
DOPA
Decarboxylase
▼
Dopamine
Figure 1. Simplified presentation of the synthesis of 
dopamine metabolism. L-DOPA = L-3,4- 
dihydroxyphenylalanine.
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neurotransmitter (Roth & Elsworth, 1995) . End-product
inhibition is primarily controlled by pteridine activity.
Specifically, when dopamine builds up in the
cytoplasm, it decreases the release of pteridine (a co­
factor for tyrosine hydroxylase). The reduced amount of
pteridine decreases tyrosine hydroxylase activity and
causes a corresponding decline in dopamine synthesis
(Cooper et al., 2003).
Autoreceptors are present at the soma, dendrites, and
nerve terminals. Stimulating autoreceptors on the nerve
terminals inhibits dopamine synthesis by reducing the
amount of pteridine. As mentioned above, pteridine
modulates the activity of tyrosine hydroxylase. Thus,
decreased pteridine causes a reduction in tyrosine
hydroxylase activity and a corresponding decrease in
dopamine synthesis and release. In contrast, stimulating
autoreceptors on the soma and dendrites (somatodendritic
autoreceptors) slows the firing rate of dopamine neurons
through a negative feedback mechanism. Both
somatodendritic and nerve terminal autoreceptors combine
to provide feedback modulation of dopaminergic
transmission (Cooper et al., 2003).
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Termination of Dopamine Transmission
Dopaminergic transmission is primarily terminated by
uptake of the released neurotransmitter back into the axon
terminal. The dopamine transporter is responsible for
this reuptake action (Cooper et al., 2003) . The dopamine
transporter is found only in dopamine neurons, thus it is
a unique marker for dopaminergic neurons (Kuhar, 1998).
Dopamine is catabolized by the actions of two enzymes
Monoamine oxidase (MAO) and catechol-O-methyltransferase
(COMT) (see Figure 2) (Cooper et al., 2003) . MAO, which is
found in the mitochondrial membranes of neurons and glial
cells, transforms dopamine to a corresponding aldehyde
(Cooper et al., 2003). More specifically, when MAO
oxidizes dopamine, dihydroxyphenylacetaldehyde (DOPAL) is
produced. DOPAL is subsequently metabolized by aldehyde 
dehydrogenase into 3,4-dihydroxyphenylacetic acid (DOPAC).
DOPAC then diffuses out of the cell and is transformed
into homovanillic acid (HVA) by COMT (Cooper et al. , 2003)
16
Figure 2. Metabolism of dopamine in the dopaminergic 
nerve terminal and synapse. MAO = monoamine oxidase, 
DOPAL = dihydroxyphenylacetaldehyde, AD = aldehyde 
dehydrogenase, DOPAC = 3,4-dihydroxyphenylacetic acid, 
COMT = catechol-O-methyltransferase, HVA = homovanillic 
acid.
17
CHAPTER FOUR
EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS
Systemic Administration of Dopamine Agonists and 
Antagonists in Adult Rats
Non-selective dopamine receptor agonists (e.g.,
R(-)-propylnorapomorphine (NPA) or apomorphine) bind to
pre- and postsynaptic D2-like receptors as well as
postsynaptic Dl-like receptors (for a review, see Arnt,
1987). When these drugs are systemically injected, adult
animals exhibit dose-dependent increases in locomotor 
activity, rearing, grooming, sniffing, and oral behaviors 
(Harkin, Kelly, Frawley, O'Donnell, & Leonard, 1999;
I
Havemann, Magnus, Moller, & Kuschinsky, 1986; Meller,
Bordi & Bohmaker, 1988). Apomorphine also causes a dose- 
dependent increase in straub tail behavior (i.e., the tail 
forms an angle of at least 30°) (Zarrindast, Bayat, &
Shafaghi, 1992). Depending on receptor occupancy, a
continuum of behaviors can be observed. Lower doses of
non-selective dopamine agonists cause non-stereotyped
behaviors (e.g., grooming, locomotor activity, and
rearing), while higher doses cause more intense
18
stereotyped behaviors (patterned locomotor activity,
sniffing, and oral behaviors).
Selective stimulation of the dopamine receptor
subtypes produces characteristic behavioral patterns. For
example, selective stimulation of Dl-like receptors with
SKF 38393 causes increased grooming, non-stereotyped
sniffing, rearing, and locomotor activity (Giorgi,
DeMontis, Porceddu, Mele, Calderini, Toffano, & Biggio,
1987; Meller et al., 1988; Molloy & Waddington, 1984). On
the other hand, more intense behaviors are observed when
D2-like agonists (i.e., quinpirole and bromocriptine) are
administered. Animals show increased head shakes
(Gonzalez-Lima, Stiehl, & Medina, 1984), locomotor
activity (Arnt & Hyttel, 1990), straub tail behavior
(Zarrindast et al., 1992), sniffing, and oral behavior
(Meller et al., 1988). These agonist-elicited behaviors
are blocked by dopamine antagonists. For example, SKF
38393-induced grooming behavior is attenuated by SCH 23390
(a Dl-like antagonist), while NPA-induced locomotor
activity, rearing, and sniffing behaviors are attenuated
by sulpiride (a D2- like antagonist) (Arnt, 1987; Clark &
White, 1987).
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Central Administration of Dopamine Agonists and 
Antagonists in Adult Rats
Microinjecting selective or non-selective Dl-like or
D2-like agonists elicit different responses depending on
brain area and dosage of injection. For example,
injecting a non-selective dopamine receptor agonist (NPA)
into the dorsal striatum elicits stereotyped behaviors
(Bordi, Carr, & Meller, 1989). More specifically, dose-
dependent increases in the intensity and duration of
sniffing and oral stereotypies were observed after
injecting NPA into sub-regions of the dorsal striatum.
Higher doses of NPA created more intense and longer
durations of these stereotypical behaviors (Bordi et al.,
1989) .
On the other hand, biphasic drug effects are observed
when the selective D2-like agonist quinpirole is injected
into the dorsal striatum. For example, rats showed
increased locomotor activity when a high dose of
quinpirole was bilaterally injected into the dorsal
striatum; however, rats showed decreased locomotor
activity when a low dose of quinpirole was microinjected
into the same region (Van Hartesveldt, Cottrell, Potter, &
Meyer, 1992). In a similar experiment, microinjecting
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quinpirole into the dorsal striatum caused a dose-
dependent decrease in locomotor and rearing behavior
(Canales & Iversen, 1998; Swanson, Heath, Stratford, &
Kelley, 1997), while causing an increase in stereotyped
behavior (Canales & Iversen, 1998). In addition,
microinjecting quinpirole into the dorsal striatum
increased yawning (Canales & Iversen, 1998).
Surprisingly, very different effects were found when
centrally administering the Dl-like agonist SKF 38393 into
the dorsal striatum. Specifically, when SKF 38393 was
microinjected into the dorsal striatum, there were no
observable changes in behavior (i.e., locomotor activity
and stereotypy). However, after 3-4 hr, rats exhibited a
decrease in "still" behavior, as well as an increase in
oral behavior (Delfs & Kelley, 1990).
Injecting non-selective and selective agonists into
the ventral striatum (i.e., nucleus accumbens) caused a
different pattern of results. When the non-selective
dopamine agonist, apomorphine, was injected into the
ventral striatum, it caused a dose-dependent reduction in
locomotor activity. More specifically, when a low dose of
apomorphine (1 - 1000 ng) was microinjected into the
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ventral striatum, there was no change in locomotor
activity; however, a higher dose of apomorphine (10 jig)
caused a significant decrease in locomotor activity (Barik
& de Beaurepaire, 1996). Likewise, when quinpirole was
microinjected into the ventral striatum, a reduction of
both locomotor activity and rearing was observed, however
stereotyped behaviors became more prominent (Canales &
Iversen, 1998) .
Different patterns of effects are observed when
selective Dl-like agonists are microinjected into the
ventral striatum. Direct Dl-like agonists (SKF 38393 or
SKF 82958) cause significant dose-dependent increases in
locomotor activity and rearing (Swanson et al., 1997) .
Systemic Administration of Dopamine Agonists and 
Antagonists in Preweanling Rats
When non-selective dopamine receptor agonists (e.g.,
NPA or apomorphine) are systemically given to young rats
they exhibit very similar behavioral effects as adults,
including increased grooming, locomotor activity, sniffing,
and intense stereotypies (McDougall & Bolanos, 1994;
Mestlin & McDougall, 1992; Shalaby & Spear, 1980). More
specifically, apomorphine increased locomotor activity at
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all ages tested (PD 7, PD 14, PD 21, PD'28, and PD 35),
but stereotyped sniffing was not observed until PD 21
(Shalaby & Spear, 1980) . Similar effects were found using
NPA, as this non-selective dopamine receptor agonist
increased locomotor activity at PD 17 and stereotyped
sniffing at both PD 11 and PD 17 (McDougall & Bolanos,
1994) .
When selective dopamine Dl-like or D2-like agonists
are given, young rats again show behavioral patterns
similar to adults (McDougall, Arnold, & Nonneman, 1990) .
For example, 11- and 17-day-old rats showed increased
locomotor’activity and grooming after being treated with
SKF 38393 (a Dl-like agonist) (McDougall et al., 1990).
In addition, the D2-like agonist quinpirole increased
locomotor activity in preweanling rats, an effect that was
antagonized by either SCH 23390 (a Dl-like antagonist) or
sulpiride (a D2-like antagonist).
Interestingly, some dose-dependent effects are
observed across early ontogeny. For example, quinpirole
caused a dose-dependent increase in locomotor activity
from PD 10 to PD 20; however, quinpirole-induced
locomotion subsequently declined at PD 30 and PD 60 (Van
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Hartesveldt, Meyer, & Potter, 1994). In addition, SKF
38393-induced grooming and quinpirole-induced vertical
movement was observed at PD 21, but not at PD 3 or at PD
10 (Moody & Spear, 1992). In summary, there are some
drug-induced ontogenetic effects, but research typically
shows that dopamine agonists and antagonists cause
qualitatively similar effects across the life-span.
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CHAPTER FIVE
EFFECTS OF PARTIAL DOPAMINE D2-LIKE AGONISTS
ON UNLEARNED BEHAVIOR
Systemic and Central Administration of Partial D2-Like 
Agonists in Adult Rats
Partial D2-like agonists have both agonistic and
antagonistic effects on behavior (Spealman, 1995); however,
the preponderance of studies indicates that partial D2-
like agonists have antagonistic effects (Kikuchi, Tottori,
Uwahodo, Hirose, Miwa, Oshiro, SPMorita, 1995; for a
review, see Pulvirenti & Koob, 1994). For example,
partial D2-like agonists (e.g., SDZ 208-911, SDZ 208-912,
OPC-14597, (-)-3-PPP, and terguride) reduce amphetamine-
or apomorphine-induced locomotion and stereotyped behavior
(Clark et al., 1991; Kikuchi et al., 1995) . Further,
apomorphine-induced hyperlocomotion, cataplexy, and
stereotyped behavior were blocked by the partial D2-like
agonist terguride (Kohler & Herbster, 1987). Consistent
with its actions as an antagonist drug, microinjecting the
partial D2-like agonist (-)-3-PPP into the ventral
striatum, but not the dorsal striatum, decreased
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exploratory behavior in adult rats (Svensson & Ahlenius,
1983) .
Partial D2-like agonists seldom exhibit agonistic
effects when tested on behavioral paradigms. However, one
example of an agonistic effect is provided by Arnt and
Perregaard (1987), because co-administration of B-HR 920
(a partial D2-like agonist) and SKF 38393 (a direct Dl-
like agonist) induced contralateral turning in
hemitransectioned-rats. A few other examples of
agonistic-like effects are available, as the stimulus
effects of cocaine were increased by administering SDZ
208-911 to monkeys (Spealman, 1995). In addition, Orsini
et al. (2001) demonstrated the agonistic effects of
terguride by measuring saccharin-reinforced responding in
dopamine-depleted rats. Normally, rats exhibit suppressed
responding for a natural reward (e.g., saccharin) when
they are in a state of low dopaminergic tone; however,
terguride exhibited agonistic properties by reversing this
effect. In conclusion, partial D2-like agonists exhibit
both agonistic and antagonistic properties in adult rats.
Partial D2-like agonists typically act as antagonists in
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behavioral models but, in a few circumstances, partial D2-
like agonists have been shown to act like agonists.
Systemic Administration of Partial D2-Like Agonists in 
Preweanling Rats
Partial D2-like agonists have both agonistic and
antagonistic behavioral effects in adult animals; however,
it is not known whether a similar pattern of effects is
evident in younger animals. In studies conducted by
McDougall and colleagues (2005),'antagonistic effects of
partial D2-like agonist were found. More specifically,
terguride was able to block NPA-, amphetamine-, and
cocaine-induced locomotor activity (McDougall, Hernandez,
Reichel, & Farley, 2005; Sibole, Matea, Krall, & McDougall,
2003). Interestingly, terguride also reduced locomotor
activity under the- saline condition as well. This
indicates that terguride acts as an antagonist under
conditions of normal and enhanced dopaminergic tone in
preweanling animals.
As with terguride, the partial D2-like agonist (-)-3-
PPP induces antagonistic effects in preweanling rats.
More specifically, young rats (PD 11 and PD 20) exhibited
increased locomotor activity when injected with the full
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D2-like agonist (+)-3-PPP, but no effect was found when
they were injected with the partial D2-like agonist (-)-3-
PPP (Arnt, 1983). In addition, when (-)-3-PPP was given
to rats at PD 11, PD 20, or PD 30, it antagonized
amphetamine-induced hyperactivity, however this effect was
not observed after treatment with (+)-3-PPP (Arnt, 1983).
Interestingly, the preponderance of studies have
shown that partial D2-like agonists have pronounced
antagonistic effects during the preweanling period (Arnt,
1983; McDougall et al., 2005; Sibole et al., 2003);
however, evidence of agonistic properties has not been
found. McDougall et al. (2005) used either an escalating
regimen of amphetamine or AMPT (a tyrosine hydroxylase
inhibitor) to induce states of low dopaminergic tone in
preweanling rats. Rats were then given an injection of
saline, terguride, or NPA. The full D2-like agonist NPA
enhanced locomotor activity in states of low dopaminergic
tone, whereas terguride did not stimulate locomotor
activity. These behavioral results suggest that partial
D2-like agonists do not exhibit agonistic properties
during the preweanling period.
28
While a few studies have shown that partial D2-like
agonists act like agonists in adult rats, comparable
studies have not shown agonistic actions in young animals
under a state of low dopaminergic tone. There are a
number of possible explanations for this apparent
ontogenetic difference. First, during amphetamine
withdrawal (a state of low dopaminergic tone), terguride
may not have induced agonistic effects because of a
substantial receptor reserve. More specifically,
reducing dopaminergic tone is believed to "create a
receptor reserve where none had existed before" (Meller et
al., 1987), and it should cause partial D2-like agonists
to exhibit agonistic effects. However, it is possible
that preweanling rats have a very large receptor reserve,
thus even under a state of low dopaminergic tone terguride
was not able to produce agonist-like effects (McDougall et
al., 2005).
Second, terguride may not act like an agonist under a
state of low dopaminergic tone due to a presumed
immaturity of D2-like receptors. According to Carlsson
(1983), the conformation of a receptor changes depending
on intrinsic activity (see also Clark et al., 1985;
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Drukarch & Stoof, 1990). Theoretically, partial D2-like
agonists should act as agonists under low dopaminergic
tone (i.e., low intrinsic activity), because of
conformational changes in the D2-like receptor. It is
possible that during the preweanling period these
conformational changes may not occur in the same manner in
adulthood.
Lastly, terguride may not have elicited agonistic
effects under a state of low dopaminergic tone because of
paradigmatic considerations. Specifically, in the
McDougall et al. (2005) study, a state of low dopaminergic
tone was presumably induced by AMPT or an escalating
regimen of amphetamine. It is possible that neither of
these manipulations was sufficient to induce a state of
low dopaminergic tone in preweanling rats. Therefore, it
remains possible that partial D2-like agonists will
exhibit agonistic properties in preweanling rats if
manipulations cause a more intense or prolonged reduction
in dopamine levels. In light of these considerations, the
use of non-behavioral paradigms (i.e., measuring
autoreceptor mediated changes in dopamine synthesis) may
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be necessary to determine whether partial D2-like agonists
exhibit agonistic properties during the preweanling period
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CHAPTER SIX
DOPAMINE SYNTHESIS
Effects of Full Dopamine D2-Like Drugs 
on Dopaminergic Synthesis
Dopamine synthesis is frequently defined as the
accumulation of L-DOPA after treatment with the aromatic
amino acid decarboxylase inhibitor, 3-
hydroxybenzylhydrazine hydrochloride (NSD 1015)(Cooper et
al. , 2003) . One of the primary ways to determine the
agonistic and antagonistic effects of dopaminergic drugs
is to assess drug-induced changes in dopamine synthesis.
For example, when the D2-like agonist, N-0437, is given to
NSD 1015-treated rats, DOPA accumulation declines.
Similarly, dorsal striatal DOPA accumulation is reduced
when NSD 1015-treated rats are injected with amphetamine,
NPA, or apomorphine (Argiolas, Melis, Fadda, Serra, &
Gessa, 1982) . Conversely, the D2-like antagonist
haloperidol causes a dose-dependent increase in DOPA
accumulation in NSD 1015-treated rats (Svensson, Eriksson,
Sc Carlsson, 1993) .
It is also of interest to determine the effects of
dopamine agonists and antagonists during a state of low
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dopaminergic tone. To that end, reserpine, which is a
dopamine depleting agent (Ahlenius,•Hillegaart, &
Wijkstrom, 1991; Argiolas et al., 1982; Guldberg & Broch,
1971; Roth & Stone, 1968), is frequently used to create a
state of low dopaminergic tone (Svensson, Ekman, Piercey,
Hoffman, Lum, & Carlsson, 1991). After acute
administration of reserpine, the D2-like agonist
quinpirole causes a dose-dependent decrease in dorsal
striatal DOPA accumulation, whereas haloperidol or
sulpiride (D2-like antagonists) increase DOPA accumulation
(Ahlenius et al., 1991; Argiolas et al., 1982; Svensson et
al., 1991). This phenomenon is regulated by dopamine
autoreceptors in the dorsal striatum (Murrin & Roth, 1987) 
Autoreceptor-mediated effects can also be examined by
measuring DOPA accumulation after treatment with the 
impulse inhibitor y-butyrolactone (GBL) (Bannon, Michaud,
& Roth, 1981; Kehr, 1984). Not surprisingly, GBL
dramatically increases DOPA accumulation in the dorsal
striatum (Bannon et al., 1981; Kehr, 1984). Apomorphine
reverses this GBL-induced increase in DOPA accumulation,
whereas haloperidol accelerates dopamine synthesis in the
striatum (Bannon et al., 1981). Thus, full agonists and
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antagonists differentially affect GBL-induced DOPA
accumulation.
Effects of Partial Dopamine D2-Like Agonists 
on Dopaminergic Synthesis
Partial D2-like agonists bind to autoreceptors, but
their intrinsic activity is less than full agonists (Lahti,
Mutin, Cochrane, Tepper, Dijkstra, Wikstrom, & Tamminga,
1996; Lahti, Weiler, Corey, Lahti, Carlsson, & Tamminga,
1997). In a state of high dopaminergic tone, partial D2-
like agonists typically act like antagonist drugs. For
example, the partial D2-like agonist (-)-3-PPP causes a
dose-dependent decline in DOPA accumulation in NSD 1015-
treated rats; however, a dose-dependent increase in DOPA
accumulation was observed after administration of the full
agonist ( + )-3-PPP (Clark, Salah, & Galloway, 1991) .
Similarly, SDZ 208-911 and terguride dose-dependently
reduced striatal DOPA accumulation (after treatment with
NSD 1015) by 80%, whereas SDZ 208-912 only produced a 32%
reduction (Svensson et al., 1991). SDZ 208-911 and
terguride partially reversed (by approximately 50%) the
GBL-induced increase in striatal DOPA accumulation, but
SDZ 208-912, which is a weaker partial agonist, was
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inactive under the same conditions. In summary, evidence
suggests that partial D2-like agonists function like
antagonists during states of high dopaminergic tone.
Pretreatment with the dopamine depleting agent
reserpine creates a state of low dopaminergic tone: a
situation where partial D2-like agonists function like
agonist drugs. For example, terguride and SDZ 208-911,
like quinpirole, reduce DOPA accumulation (after injection
of NSD 1015) in the dorsal striatum by approximately 80%
(Svensson et al., 1991). D2-like antagonists, on the
other hand, increase striatal DOPA accumulation in
reserpinized rats (Argiolas et al., 1982) .
The impulse inhibitor GBL also induces a functional
state of low dopaminergic tone. Not surprisingly, GBL-
induced DOPA accumulation is inhibited by both full (e.g.,
quinpirole) and partial (e.g., terguride, SDZ 208-911,
OPC-14597, and OPC-4392) D2-like agonists (Ahlenius et al.,
1991; Clark, Hjorth, & Carlsson, 1984; Kikuchi et al. 1995;
Svensson et al., 1991). These effects of partial D2-like
agonists are subsequently blocked by the D2-like
antagonist haloperidol (Svensson, 1991) .
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CHAPTER SEVEN
SUMMARY AND HYPOTHESES
General Summary and Hypotheses
Partial D2-like agonists exhibit either agonistic or
antagonistic properties in adult rats depending on the
state of dopaminergic tone (for a review, see Clark et al.,
1985). More specifically, in adult rats, partial D2-like
agonists have antagonistic effects under a state of high
dopaminergic tone, and agonistic effects under a state of
low dopaminergic tone (for a review, see Pulvirenti & Koob,
1994) .
A somewhat different pattern of effects are observed
in early ontogeny. In preweanli'ng rats, partial D2-like
agonists function as antagonists in states of high.1
dopaminergic tone (Arnt, 1988; McDougall et al., 2005;
Sibole et al., 2003). In states of low dopaminergic tone,
however, partial D2-like agonists continue to function
like antagonist drugs (McDougall et al., 2005). In other
words, terguride consistently functioned like an
antagonist drug in behavioral paradigms using the
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preweanling rat: effects that were apparent during states
of low or high dopaminergic tone.
In addition to employing behavioral paradigms, the
effects of partial D2-like agonists have been examined by
measuring autoreceptor-mediated changes in dopamine
synthesis (Iyengar, Hausler, Kim, Marient, Alter, & Wood,
1989; Lahti et al., 1996; Li, Ichikawa, Dai, & Meltzer,
2004). In states of high dopaminergic tone (no reserpine
or GBL treatment), partial D2-like agonists exhibit
antagonistic (haloperidol-like) effects in adult rats
(Ahlenius et al., 1991; Argiolas et al., 1982; Svensson et
al., 1991). On the other hand, in states of low
dopaminergic tone (i.e., after reserpine or GBL treatment) 
partial D2-like agonists exhibit agonistic (quinpirole-
like) effects in adults.
In summary, in both behavioral and neurochemical 
paradigms involving adult rats, partial D2-like agonists
function as antagonists during states of high dopaminergic
tone, but function as agonists in states of low
dopaminergic tone. In contrast, available behavioral
evidence suggests that partial D2-like agonists function
exclusively as antagonists during the preweanling period
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(Arnt, 1983; McDougall et al., 2005; Sibole et al., 2003).
However, no ontogenetic studies have directly examined the
effects of partial D2-like agonists using neurochemical
paradigms.
The purpose of this thesis, therefore, was to
determine the effects of partial D2-like agonists on
dorsal striatal dopamine synthesis during the preweanling
period. To this end, preweanling rats were treated with
saline or reserpine (either acutely or repeatedly) in
Experiment 1. On the test day, the saline- or reserpine-
pretreated rats were injected with the partial D2-like
agonist terguride, the full D2-like agonist quinpirole, or
the full D2-like antagonist haloperidol. Rats were then
injected with NSD 1015. It was hypothesized that
terguride would induce antagonistic (haloperidol-like)
effects in a state of high dopaminergic tone (after saline
treatment), while showing agonistic (quinpirole-like)
effects in a state of low dopaminergic tone (after
repeated reserpine treatment). • It was also hypothesized
that terguride would induce antagonistic effects after
acute reserpine treatment.
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The rationale for these hypotheses was based on the
intensity and longevity of dopamine depletion. McDougall
et al. (2005) showed that short-term or mild dopamine
depletion was insufficient to cause terguride to exhibit
agonist-like properties. Therefore, I hypothesized that
prolonged dopamine depletion (i.e., after repeated
reserpine treatment) would induce a state of dopaminergic
tone sufficiently low to cause agonistic effects in
terguride-treated rats. Because acute administration of
AMPT did not induce agonist-like effects in terguride-
treated rats (see McDougall et al., 2005), it was
hypothesized that acute reserpine treatment would also be
insufficient to induce a state of low dopaminergic tone.
If the data do not support these hypotheses (i.e., if
terguride causes antagonist-like effects in Experiment 1), 
then it is possible that preweanling rats have a smaller
receptor reserve than adult rats. Alternatively,
preweanling rats may not show adult-like changes in
receptor conformation after dopamine depletion.
Experiment 2 was designed to examine the effects of
terguride using GBL. The GBL model is a technique used to
induce a state of low dopaminergic tone by inhibiting
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nerve impulse flow (Walters & Roth, 1976) . In adult rats,
GBL-induced DOPA accumulation is inhibited by both partial
and full D2-like agonists (Ahlenius et al., 1991; Clark et
al., 1984; Kikuchi et al. 1995; Svensson et al., 1991).
Importantly, the effects of partial D2-like agonists on
GBL-induced DOPA accumulation have not been assessed in
preweanling rats. Therefore, preweanling rats were
injected with terguride, quinpirole, or haloperidol. Rats
were subsequently injected with GBL prior to NSD 1015
treatment. It was predicted that terguride would exhibit
agonistic (quinpirole-like) properties (i.e., reversing
GBL-induced DOPA accumulation). This pattern of results
would indicate that partial D2-like agonists cause
agonistic effects during’ a state of low dopaminergic tone.
Lastly, Experiment 3 was designed to examine whether
haloperidol would block terguride's effects using the GBL
model. Preweanling rats were injected with saline or
haloperidol, followed by an injection of saline, terguride,
or quinpirole. Rats were then treated with GBL followed
by NSD 1015. It was predicted that haloperidol would
block the ability of terguride and quinpirole to reverse
GBL-induced DOPA accumulation. This pattern of results
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would indicate that: 1) the actions of terguride are
mediated by dopamine receptors; and 2) terguride and
quinpirole are functioning like agonists, while
haloperidol is functioning like an antagonist.
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CHAPTER EIGHT
GENERAL METHODS
Subj ects
Subjects were 240 male and female Sprague-Dawley rats
(Charles River), born and raised in the animal colony at
California State University, San Bernardino. All litters
were culled to 10 by PD 3 and the pups remained with the
dam throughout testing. Before the pretreatment period,
rats were randomly assigned to treatment groups. All
subjects were given food and water ad lib. The colony
room was maintained at 21 - 23°C, and was on a 12 light/12
dark cycle. All subjects were treated in accordance with
the ethical principles as outlined by the American
Psychological Association (1992).
Drugs
Terguride, haloperidol, quinpirole, NSD 1015 (3-
hydroxybenzylhydrazine hydrochloride), and GBL (y-
butyrolactone) were dissolved in saline. Reserpine was
dissolved in a minimal amount of glacial acetic acid and
diluted with saline. All drugs were purchased from Sigma
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(St. Louis, MO) and were injected intraperitoneally (ip) 
at a volume of 5 ml/kg.
Apparatus
A high performance liquid chromatograph (582 pump and
a MD-150 column; ESA, Chelmsford, MA) with an
electrochemical detector (Coulochem II; ESA) was used to
measure DOPA accumulation. The mobile phase consisted of
75 mM NaH2PO4, 1.4 mM 1-octane sulfonic acid, 10 mM EDTA,
I
and 10% acetonitrile [(pH 3.1) MD-TM Mobile Phase; ESA]
and was pumped at a rate of 0.5 ml/min.
Assay Procedures
Frozen dorsal striatal sections were sonicated in 10
volumes of 0.1 N HC1O4 and centrifuged at 20,000 x g for 3 0
min at 4°C. The supernatant was then filtered through a
0.22 pirn centrifugation unit at 2,000 x g for 5 min at 4°C.
Twenty microliters of the resulting extract was assayed
for DOPA accumulation using high performance liquid
chromatography.
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Statistical Analysis
Analysis of variance (ANOVA) was used to analyze 
neurochemical data. Litter effects were controlled by
assigning no more than one subject per litter to a
particular treatment group. Post-hoc comparison of the
neurochemical data was conducted using Tukey tests (p
< .05) .
I
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CHAPTER NINE
EXPERIMENT ONE
Overview
Experiment 1 examined whether terguride has
agonistic-like effects during states of low dopaminergic
tone and antagonistic-like effects during states of high
dopaminergic tone. To that end, dopamine synthesis (i.e.,
DOPA accumulation after treatment with NSD 1015) was
measured in saline- or reserpine-treated preweanling rats
(acute or repeated treatment). Rats in the acute
condition received one reserpine injection and rats in the
repeated condition received reserpine treatment for five
consecutive days (see procedure for more details). In
control animals, it was predicted that terguride, like
haloperidol, would enhance dopamine synthesis. Conversely,
terguride was hypothesized to act like quinpirole in
reserpinized rats (i.e., dopamine synthesis would/be
depressed). It was also predicted that terguride would
inhibit dopamine synthesis in the repeated reserpine
condition but not in the acute reserpine condition group.
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Procedures
Preweanling rats (n = 144) were randomly divided into
three conditions: control, repeated reserpine, and acute
reserpine. Rats in the control condition received saline
injections on PD 16 - PD 20; rats in the repeated
reserpine condition received reserpine (1 mg/kg, ip) 
injections on PD 16 - PD 20; rats in the acute reserpine
condition received a single injection of reserpine (1
mg/kg, ip) on PD 20. After 24 hr, all rats were injected 
with the full D2-like antagonist haloperidol (0.5 mg/kg, 
ip), the partial D2-like agonist terguride (0.1, 0.4, or 
1.6 mg/kg, ip), the full D2-like agonist quinpirole (0.5 
mg/kg, ip), or saline (n = 8 per group). After an
additional 30 min, rats were injected with NSD 1015 (100
mg/kg, ip). Rats were then sacrificed 30 min later and
their dorsal striata were stored at -70°C until time of
assay (see Table 1).
Statistics
A 3 x 6 (pretreatment condition x post treatment)
ANOVA was used to determine whether DOPA levels differed
46
Table 1. Injection paradigm of Experiment 1.
I
Condition PD
Repeated
Reserpine 16-20
Saline 16-20
Acute
Reserpine 20
First
Injection Time
Second
Inj ection Time
Terguride 3 0 min NSD 1015 3 0 min Sacrifice
Quinpirole 3 0 min NSD 1015 3 0 min Sacrifice
Haloperidol 3 0 min NSD 1015 3 0 min Sacrifice
Saline 3 0 min NSD 1015 3 0 min Sacrifice
IRats were pretreafed with' reserpine or saline. On the test 
day, rats were injected with terguride, quinpirole, 
haloperidol, or saline. All rats were then injected with 
NSD 1015. '
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according to treatment group. DOPA accumulation after NSD
1015 treatment was used as an index of dopamine synthesis.
Results
Pretreatment condition interacted with post treatment
group to affect striatal DOPA accumulation [F (10,90) =
20.19, p < 0.001] (see Fig. 3). In the vehicle-
pretreatment condition, the partial D2-like agonist
terguride had antagonist-like effects in vehicle-
pretreat ed rats (under high dopaminergic tone), because
both haloperidol and terguride caused a significant
increase in DOPA accumulation when compared to the control
group [F (5, 30) = 63.77, p < 0.001]. In addition,
haloperidol caused a greater increase in DOPA accumulation
than did terguride. More specifically, haloperidol caused
a 313% increase in DOPA accumulation, while terguride
caused a 165% increase over control values. On the other
hand, the D2-like agonist quinpirole significantly reduced
DOPA accumulation in comparison to saline controls.
In the reserpine-pretreated conditions (acute and
repeated), terguride caused a quinpirole-like effect.
Both terguride and quinpirole significantly reduced DOPA
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accumulation relative to the saline controls [acute
reserpine: F (5, 30) = 79.72, p < 0.0001; repeated
reserpine: F (5, 30) = 27.86, p < 0.001]. More
specifically, all doses of terguride (0.4, 0.8, and
1.6mg/kg) significantly decreased DOPA accumulation in the 
acute reserpine condition; however, only 1.6 mg/kg
terguride decreased DOPA accumulation in the repeated
reserpine condition. Haloperidol significantly increased
DOPA accumulation in both the acute and repeated reserpine
conditions.
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CHAPTER TEN
EXPERIMENT TWO
Overview
Experiment 2 examined whether terguride caused
agonistic-like effects using the GBL model. GBL creates a
state of low dopaminergic tone by inhibiting impulse flow; 
therefore, the effects of partial and full dopamine-acting
drugs on DOPA accumulation was measured in GBL-treated
rats. It was predicted that terguride would exhibit
agonist-like (quinpirole-like) effects under a state of ■
low dopaminergic tone (in GBL-treated animals). In other
words, terguride, like quinpirole and opposite to
haloperidol, was expected to reverse GBL-induced DOPA
accumulation.
Procedures
On PD 21, preweanling rats (n = 48) were injected
with the full D2-like antagonist haloperidol (0.5 mg/kg,
ip), the partial D2-like agonist terguride (0.1, 0.4, or
1.6 mg/kg, ip), the full D2-like agonist quinpirole (0.5 
mg/kg, ip), or saline. After 25 min later, they were
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injected with GBL (625 mg/kg, ip). After an additional 5
min, an injection of NSD 1015 (100 mg/kg, ip) was given.
Rats were sacrificed 30 min later and their dorsal striata
were stored at -70°C until time of assay (see Table 2).
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Table 2. Injection paradigm for Experiment 2.
First
Inj ection Time
Second
Inj ection Time
Third
Injection Time
Terguride 25 min GBL 5 min NSD 1015 3 0 min Sacrifice
Quinpirole 25 min GBL 5 min NSD 1015 3 0 min Sacrifice
Haloperidol 25 min GBL 5 min NSD 1015 3 0 min Sacrifice
Saline 25 min GBL 5 min NSD 1015 3 0 min Sacrifice
Rats were first injected with terguride, quinpirole, 
haloperidol, or saline. They were then given an injection 
GBL prior to NSD 1015.
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Statistics
A one-way (treatment group) ANOVA was used to
determine whether DOPA levels differed according to
treatment group. DOPA accumulation after NSD 1015
treatment was used as an index of dopamine synthesis.
Results
As expected, the partial D2-like agonist terguride
(0.1, 0.2, 0.8, and 1.6 mg/kg) and the full D2-like
agonist quinpirole significantly reduced DOPA accumulation
(see Fig. 4) [F (7, 40) = 16.27, p < 0.001].
Interestingly, quinpirole caused a greater reduction in
DOPA accumulation than terguride. On the other hand,
haloperidol significantly increased DOPA accumulation
relative to saline controls.
Surprisingly there were no dose-dependent effects
observed among the terguride groups. More specifically,
DOPA accumulation did not vary across the extended dose
range (0.1-1.6 mg/kg) of terguride. This result may be
due to a "ceiling effect" of the partial D2-like agonist,
with 0.1 mg/kg terguride producing a maximal effect on
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Results from Experiment 2. aSignificantly 
from saline controls (p < 0.05). bSignificantly 
from terguride groups (p < 0.05).
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DOPA accumulation. This possibility seems unlikely,
because terguride has previously been shown to produce
dose-dependent effects across the same range of doses used
in the present experiment (Clark et al., 1991). In the
latter study, however, terguride's effects were assessed
in a behavioral paradigm using adult rats.
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CHAPTER ELEVEN
EXPERIMENT THREE
Overview
Experiment 3 examined the combined effects of
terguride and haloperidol using the GBL model.
Preweanling rats were pretreated with both GBL and NSD
1015. Rats were then injected with saline or haloperidol
followed by a later injection of saline, terguride, or
quinpirole. It was predicted that terguride and
quinpirole would reverse GBL-induced DOPA accumulation,
and that this effect would be blocked by haloperidol.
This pattern of results would indicate that the actions of
terguride are mediated by dopamine receptors. It would
also indicate that terguride and quinpirole were
exhibiting agonistic properties during a state of low
dopaminergic tone, while haloperidol was acting as an
antagonist.
Procedures
On PD 21, preweanling rats (n = 48) were injected
with saline or the full D2-like antagonist haloperidol
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(0.5 mg/kg, ip) followed, 30 min later, by an injection of 
the partial D2-like agonist terguride (dose to be
determined in Experiment 2), the full D2-like agonist
quinpirole (0.5 mg/kg, ip), or saline. After an
additional 25 min, rats were injected with GBL (625 mg/kg,
ip), followed, 5 min later, by an injection of NSD 1015
(100 mg/kg, ip). Rats were sacrificed 30 min later and
their dorsal striata were stored at -70°C until time of
assay (see Table 3).
Statistics
A 2 x 3 (pretreatment condition x post treatment)
ANOVA was used to determine whether DOPA levels differed
according to treatment group. DOPA accumulation after NSD
1015 treatment was used as an index of dopamine synthesis.
Results
As expected, both terguride (0.8 and 1.6 mg/kg) and
quinpirole significantly reduced DOPA accumulation when
compared to control values [F (4, 50) = 7.66, p < 0.001]
(see Fig. 5), with quinpirole's effects being more robust.
58
Table 3. Injection paradigm for Experiment 3.
First
Injection Time
Second
Injection Time
Third
Injection Time
Fourth
Injection Time
Haloperidol
30
min Terguride
25
min GBL
5
min NSD 1015
30
min Sacrifice
Saline
30
min Quinpirole
25
min GBL
5
min NSD 1015
30
min Sacrifice
Saline
25
min GBL
5
min NSD 1015
30
min Sacrifice
On the test day (PD 21), rats were first injected with 
haloperidol or saline. After the fist drug 
administration, they were injected with terguride, 
quinpirole, or saline. They were then injected with GBL 
and NSD 1015.
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Figure 5. 
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Results from Experiment 3. aSignificantly 
from saline controls (p < 0.05). bSignificantly 
from terguride groups (p < 0.05). cSignificantly 
from saline-pretreated rats receiving the 
dose of terguride and quinpirole (p < 0.05).
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Haloperidol significantly reversed quinpirole-induced DOPA
accumulation, however, this effect was only observed for 
one of the terguride groups (0.4 mg/kg). More
specifically, haloperidol reversed the DOPA accumulation 
caused by 0.4 mg/kg terguride, but haloperidol did not
significantly reverse the effects of the higher terguride
doses (0.8 or 1.6 mg/kg).
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CHAPTER TWELVE
DISCUSSION
Effects of Terguride After Acute and 
Repeated Reserpine Treatment
on Dopamine Synthesis in 
Preweanling Rats
The purpose of present study was to examine the
neurochemical effects of terguride under high or low
dopaminergic tone using preweanling rats. In adult rats,
partial D2-like agonists function as antagonists during
states of high dopaminergic tone, but function as agonists
in states of low dopaminergic tone using both behavioral
and neurochemical paradigms. In contrast, available
behavioral evidence suggests that partial D2-like agonists
function exclusively as antagonists during the preweanling
period (Arnt, 1983; McDougall et al., 2005; Sibole et al.,
2003); however, no ontogenetic studies have directly
examined the effects of partial D2-like agonists using
neurochemical paradigms.
In the present study, therefore, dopamine synthesis
(i.e., DOPA accumulation after treatment with NSD 1015)
was measured in saline- or reserpine-pretreated rats
(acute or repeated treatment) (Experiment 1) . Rats in the ■
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acute condition received one reserpine injection on PD 20,
while rats in the repeated condition received reserpine
treatment for five consecutive days (PD 16 - PD 20). It
was predicted that terguride would depress dopamine
synthesis after repeated reserpine treatment (low
dopaminergic tone). Conversely, it was hypothesized that
terguride would enhance dopamine synthesis in control
animals (high dopaminergic tone). It was also predicted
that terguride would not affect dopamine synthesis in the
acute reserpine condition.
These hypotheses were partially supported by the
results. As hypothesized, under a state of high
dopaminergic tone (i.e., in the vehicle-pretreated
condition), the partial D2-like agonist terguride had
antagonist-like effects. Like haloperidol, terguride
caused significant increases in DOPA accumulation when
compared to the control group. In addition, haloperidol
caused a greater increase in DOPA accumulation than
terguride. In a state of low dopaminergic tone (i.e.,
after acute or repeated reserpine treatment), terguride
caused the opposite effect (i.e., terguride had agonist­
like actions). Like the full D2-like agonist quinpirole,
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terguride reduced DOPA accumulation after acute or
repeated reserpine treatment. The reduction in DOPA
accumulation was more robust in the quinpirole group than
the terguride groups.
That terguride causes agonist-like effects after
repeated reserpine treatment was expected, but I
originally hypothesized that terguride would still act
like an antagonist after acute reserpine treatment. The
basis for the latter hypothesis was that short-term
dopamine depletion using AMPT did not cause agonistic
behavioral effects in terguride-treated rats (McDougall et 
al., 2005). Therefore, I hypothesized that repeated, but
not acute, administration of reserpine would produce a
state where terguride induced agonistic neurochemical
effects. However, the results from the present study
showed that acute administration of reserpine was
sufficient to create a state of low dopaminergic tone that
would allow terguride to exhibit agonistic effects.
Perhaps, the ability of AMPT and reserpine to induce a
state of low dopaminergic tone differs in young animals.
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Effects of Terguride on DOPA 
Accumulation in Preweanling 
Rats Using the GBL Model
In addition to using reserpine to induce a state of
low dopaminergic tone, GBL was used to examine the effects
of autoreceptor-mediated changes in neurotransmitter
synthesis. GBL creates a state of low dopaminergic tone
by inhibiting impulse flow; therefore, the effects of
partial and full dopamine-acting drugs on DOPA
accumulation was measured in GBL-treated rats. In
Experiment 2, it was predicted that terguride would
exhibit agonistic (quinpirole-like) effects in GBL-treated
animals. In Experiment 3, it was hypothesized that
terguride would reverse GBL-induced DOPA accumulation, and
that this effect would be blocked by haloperidol. This
pattern of results would indicate that the actions of
terguride were mediated by dopamine receptors.
As predicted, terguride (0.1, 0.2, 0.8, and 1.6
mg/kg), like quinpirole, significantly reversed GBL-
induced DOPA accumulation. Surprisingly, there were no
dose-dependent effects observed among the terguride groups
Although they were not significantly different from each
other, there was a dose-dependent trend (i.e., an increase
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in DOPA accumulation) up to 0.4 mg/kg and then a transient 
decline above 0.4 mg/kg. This transient effect may be due
to the unique properties of partial D2-like agonists. As
indicated before, partial D2-like agonists have high
affinity and low intrinsic activity at presynaptic sites
(Carlson, 1983). Therefore, when a partial D2-like
agonist was injected at a low dose, it showed "true"
partial agonist effects (showing high affinity but low
intrinsic effect), however, when it was given at a higher
dose, it showed more full agonist-like effects
(quinpirole-like effects). In addition, this
nonsignificant dose-dependent effect may also be due to a
"ceiling effect" of the partial D2-like agonist. As
indicated before, since there were no significant
differences among the terguride groups, it may be possible
that 0.1 mg/kg terguride was sufficient to induce a
maximal effect. Once again, quinpirole had a more robust
effect on dopamine accumulation than terguride did.
Haloperidol significantly increased DOPA accumulation
relative to the control values (see Fig. 4). Haloperidol
also significantly reversed the quinpirole-induced
reductions in DOPA accumulation. Interestingly, this
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effect was only observed in one of the terguride groups
(0.4 mg/kg). More specifically, haloperidol only blocked 
the effects of 0.4 mg/kg terguride, while the effects of 
0.8 or 1.6 mg/kg terguride were not attenuated by the
antagoni st drug.
The inability of haloperidol to block the effects of
0.8 or 1.6 mg/kg terguride suggests that some of
terguride's effects may be mediated by other receptor
systems. Unlike adult rats, preweanling rats have a DI
autoreceptor that modulates dopamine synthesis (Teicher,
Gallitano, Gelbard, Marsh, Booth, & Baldessarini, 1991).
Teicher and colleagues (1991) examined the ontogeny of DI
autoreceptor-mediated effects by comparing young and adult
rats using the GBL model. They found that Dl-like
agonists, SKF 38393 and CY 208243, significantly reduced
the GBL-induced increase in DOPA accumulation in young (PD
15-16) but not adult rats. This transient expression of
Dl-like autoreceptors suggests that both DI- and D2-like
autoreceptors are present and functional in developing
brains. In the present study, therefore, it is possible
that terguride may have been affecting DOPA accumulation
by binding to both D2 and DI autoreceptors. If true, it
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might explain why haloperidol did not fully antagonize
terguride's effects on DOPA accumulation, because
haloperidol has almost no affinity for DI receptors.
GBL Model
GBL is used to induce a state of low dopaminergic
tone by inhibiting nerve impulse flow (Walters & Roth,
1976). When impulse flow is inhibited, release of
dopamine at the terminals is disrupted, resulting in a
decrease in the synaptic levels of dopamine. Decreased
levels of synaptic dopamine result in disinhibition of
autoreceptors, which leads to increased DOPA accumulation
(Wolf & Roth, 1987). In other words, blocking impulse
flow increases dopamine synthesis by modulating
presynaptic receptors (Walters & Roth, 1976). This GBL-
induced DOPA accumulation is capable of being altered by
dopamine-acting drugs. For example, amphetamine, which
increases dopamine levels, causes a significant reduction
in GBL-induced DOPA accumulation (Walters & Roth, 1976).
Conversely, haloperidol significantly increases GBL-
induced DOPA accumulation when compared to controls. In
addition, haloperidol reverses the amphetamine-induced
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reduction in GBL-induced DOPA accumulation (Walters & Roth,
1976) .
In the present thesis, preweanling rats exhibited
adult-like neurochemical effects. Specifically,
quinpirole (a full D2-like agonist) caused a significant
reduction in GBL-induced DOPA accumulation, while
haloperidol (a D2-like antagonist) enhanced DOPA
accumulation. These results provide additional evidence
that autoreceptors are functionally mature during the late
preweanling period.
Autoreceptors in Preweanling Rats
Early studies suggested that the autoreceptors of
young animals were not functional during the early
adolescent period (Shalaby & Spear, 1980; Hedner &
Lundborg, 1985). However, results from the present study
indicate that autoreceptors function in an adult-like
manner during the late preweanling period (i.e., on PD 21).
This conclusion is consistent with a study conducted by
Andersen et al. (1997) using full D2-like agonists.
Andersen et al. (1997) measured DOPA accumulation in the
striatum, nucleus accumbens, and prefrontal cortex after
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rats were treated with (+)-7-OH-DPAT, GBL, and NSD 1015 on
PD 10, PD 15, PD 20, PD 30, and PD 40. The full D2-like
agonist (+)-7-OH-DPAT inhibited striatal GBL-induced DOPA
accumulation at all ages. These results support our
contention that autoreceptors are present and functional
during the late preweanling period.
Interestingly, Andersen et al. (1997) also found that
GBL-induced DOPA accumulation was inhibited in the
prefrontal cortex after (+)-7-OH-DPAT treatment in 10-,
15-, 20-, and 30-day-old rats. Although the present
thesis only tested the effects of terguride in the
striatum, it would be interesting to determine whether a
partial D2-like agonist affects DOPA accumulation
similarly in the prefrontal cortex of preweanling rats.
In any event, the present study was the first to show that
a partial D2-like agonist would induce adult-like
neurochemical effects during the preweanling period.
Conformational Theory
In the present study, partial agonists had opposite
neurochemical effects depending on the state of
dopaminergic tone. According to Carlsson (1983), the
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conformation of a receptor changes depending on intrinsic
activity (see also Clark et al., 1985; Drukarch & Stoof,
1990). More specifically, responsiveness of a receptor to
different agonist drugs varies depending on the state of
the receptor. The intrinsic activity and previous
occupancy of the receptor plays a very critical role. For
example, after high receptor occupancy, partial D2-like
agonists act a's antagonists; whereas after low receptor
occupancy, partial D2-like agonists act as agonists.
These changes in receptor occupancy slowly induce a
conformational change in the receptor, thus influencing
the responsiveness of the receptor. In other words, the
adaptability of receptor molecules alters the
responsiveness to partial D2-like agonists.
In the present study, the partial D2-like agonist
terguride induced agonistic effects under low receptor
occupancy (low dopaminergic tone) and antagonistic effects
under high receptor occupancy (high dopaminergic tone).
This is an important finding because it has not been
previously shown that partial agonists will induce this
pattern of effects in preweanling rats. For such effects
71
to occur, dopamine autoreceptors must be functioning in an
adult-like manner by PD 21.
Receptor Reserve Theory
An alternative explanation for the actions of partial
D2-like agonists is provided by the receptor reserve
theory. This theory suggests that partial D2-like
agonists only exhibit agonistic actions in the presence of
a large receptor reserve (Meller et al., 1987). More
specifically, because partial D2-like agonists possess low
intrinsic efficacies, they cannot stimulate a receptor-
mediated response in the absence of a substantial receptor
reserve. For example, when a full agonist (NPA) and
partial agonist ((-)3-PPP) are administered under high
receptor reserve conditions, both drugs elicit a maximal 
tissue response that is indistinguishable from one another
Thus, with a large receptor reserve, partial D2-like
agonists act like agonists (e.g., decrease DOPA
accumulation). On the other hand, partial D2-like
agonists act like antagonists (e.g., increase DOPA
accumulation) when there is little or no receptor reserve.
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In the present study, a partial D2-like agonist
elicited agonist-like and antagonist-like effects under
low and high dopaminergic tone, respectively. These
results suggest that both acute and repeated reserpine
treatment produced a large receptor reserve. Conversely,
little or no receptor reserve was present after vehicle
treatment.
When considered together, I believe that the receptor
reserve theory better explains the results of the present
study. This conclusion - is largely drawn from results of
the reserpine experiment (Experiment 1). According to
Carlsson (1983), changes in receptor occupancy are only
capable of slowly inducing a conformational change in the
receptor. However, terguride caused similar effects in
rats treated acutely or repeatedly with reserpine. Thus,
reserpine must either be capable of inducing more rapid
conformational changes than Carlsson suggests or the
conformational theory cannot fully explain the present
results.
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Clinical Aspects of Partial D2-Like Agonists
Before partial D2-like agonists were commercially
available to the public, D2-like antagonists were used to
treat schizophrenia, motor dysfunction, and drug addiction
(for a review, see Wetzel & Benkert, 1992). However, due
to their severe side effects (e.g., vomiting, diarrhea,
dizziness, drowsiness, and motor dysfunction), researchers
have been searching for drugs that do not possess these
types of extrapyramidal side effects.
Recently, partial DA agonists (e.g., aripiprazole,
preclamol, terguride, SDZ 208-911, and SDZ 208-912) have
drawn much clinical attention because of their unique
ability to "normalize" dopamine functioning, without
causing extrapyramidal side effects (Carson, Kane, Ali,
Dunber, & Ingenito, 2000; Pulvirenti et al., 1998).
Partial D2-like agonists alleviate drug withdrawal
symptoms, decrease motor dysfunction, and reduce symptoms
of schizophrenia and delusional disorders (for a review,
see Benkert, Muller-Siecheneder, & Wetzel, 1995). For
example, in a study using schizophrenic subjects,
terguride reduced both positive and negative psychotic
behaviors (Filip, Marsalek, Halkova, & Karen, 1991). In
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addition, motor dysfunction was reduced after taking the
same drug. More specifically, when terguride was given to
patients with restless leg syndrome, symptomology was
significantly reduced, and their restless leg syndrome
symptoms were improved without major side effects (Sonka,
Pretl, & Kranda, 2003). Therefore, the unique
neurochemical properties of■ partial agonists (i.e., the
ability to induce agonistic and antagonistic effects) have
proven to be of great therapeutic benefit.
Conclusion
In preweanling rats, partial D2-like agonists act as
agonists under low dopaminergic tone and as antagonists
under high dopaminergic tone. This conclusion is based on
experiments using the dopamine depleting agent reserpine
and the impulse flow inhibitor GBL. Both of these drugs
were able to create a state of low dopaminergic tone thus
causing terguride to exhibit agonist (quinpirole-like)
properties.
Results from the present thesis also indicate that
dopamine autoreceptors are present and functional by PD 21
It remains unknown whether the responsiveness of partial
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agonist drugs is altered by previous receptor occupancy
(conformational theory) or changes in receptor reserve.
Future investigation is necessary to determine which
theory accurately explains the actions of partial D2-like
agonists during the preweanling period.
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